Niels Vande Casteele1,2,3, Diane R Mould4, Jason Coarse5, Iram Hasan5, Ann Gils6, Brian Feagan7, William J Sandborn8,7. 1. Division of Gastroenterology, School of Medicine, IBD Center, University of California San Diego, 9500 Gilman Drive #0956, La Jolla, CA, 92093, USA. nvandecasteele@ucsd.edu. 2. Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Louvain, Belgium. nvandecasteele@ucsd.edu. 3. Robarts Research Institute, London, ON, Canada. nvandecasteele@ucsd.edu. 4. Projections Research Inc., Phoenixville, PA, USA. 5. UCB Pharma, Raleigh, NC, USA. 6. Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Louvain, Belgium. 7. Robarts Research Institute, London, ON, Canada. 8. Division of Gastroenterology, School of Medicine, IBD Center, University of California San Diego, 9500 Gilman Drive #0956, La Jolla, CA, 92093, USA.
Abstract
BACKGROUND: Certolizumab pegol is an effective biologic for patients with Crohn's disease (CD). Individual differences in certolizumab pegol apparent clearance (CL/F) affect exposure and possibly efficacy. A previously developed population pharmacokinetic (PK) model did not account for dynamic changes in clinical parameters during therapy. OBJECTIVE: The aim of this study was to refine the existing PK model to capture the time-varying influence of covariates. METHODS: Data collected from 2157 Crohn's disease patients in nine studies were analyzed using nonlinear mixed-effects modeling software (NONMEM). Certolizumab pegol concentration-time data were described by a one-compartment PK model with first-order absorption, and one-compartment disposition with linear, time-dependent elimination using antidrug antibody (ADAb) concentration as a continuous variable. RESULTS: The final dataset consisted of 12,926 analyzable records. Parameter estimates were absorption rate constant 1.83/day, CL/F 0.527 L/day, and apparent volume of distribution (V/F) 8.33 L. ADAb concentration (2.5-214 units/mL) increased the median CL/F by 142-174%. For a typical patient, body weight (46.8-100.5 kg) increased the median CL/F and V/F from 82 to 120%. Albumin (32-48 g/L) decreased and C-reactive protein (0.5-54.0 mg/L) increased the median CL/F from 123 to 85% and from 83 to 113%, respectively. Between-patient variability of CL/F was 19.6%. CONCLUSIONS: By incorporating time-varying covariates, this population PK model reduces between-patient variability on CL/F estimates, and the relative influence of ADAb can now be assessed. As Crohn's disease patient covariates are often time-dependent, this model is more reflective of patient drug exposure with sustained treatment.
BACKGROUND:Certolizumab pegol is an effective biologic for patients with Crohn's disease (CD). Individual differences in certolizumab pegol apparent clearance (CL/F) affect exposure and possibly efficacy. A previously developed population pharmacokinetic (PK) model did not account for dynamic changes in clinical parameters during therapy. OBJECTIVE: The aim of this study was to refine the existing PK model to capture the time-varying influence of covariates. METHODS: Data collected from 2157 Crohn's diseasepatients in nine studies were analyzed using nonlinear mixed-effects modeling software (NONMEM). Certolizumab pegol concentration-time data were described by a one-compartment PK model with first-order absorption, and one-compartment disposition with linear, time-dependent elimination using antidrug antibody (ADAb) concentration as a continuous variable. RESULTS: The final dataset consisted of 12,926 analyzable records. Parameter estimates were absorption rate constant 1.83/day, CL/F 0.527 L/day, and apparent volume of distribution (V/F) 8.33 L. ADAb concentration (2.5-214 units/mL) increased the median CL/F by 142-174%. For a typical patient, body weight (46.8-100.5 kg) increased the median CL/F and V/F from 82 to 120%. Albumin (32-48 g/L) decreased and C-reactive protein (0.5-54.0 mg/L) increased the median CL/F from 123 to 85% and from 83 to 113%, respectively. Between-patient variability of CL/F was 19.6%. CONCLUSIONS: By incorporating time-varying covariates, this population PK model reduces between-patient variability on CL/F estimates, and the relative influence of ADAb can now be assessed. As Crohn's diseasepatient covariates are often time-dependent, this model is more reflective of patient drug exposure with sustained treatment.
Authors: L S Kiss; T Szamosi; T Molnar; P Miheller; L Lakatos; A Vincze; K Palatka; Z Barta; B Gasztonyi; A Salamon; G Horvath; G T Tóth; K Farkas; J Banai; Z Tulassay; F Nagy; M Szenes; G Veres; B D Lovasz; Z Vegh; P A Golovics; M Szathmari; M Papp; P L Lakatos Journal: Aliment Pharmacol Ther Date: 2011-08-24 Impact factor: 8.171
Authors: W J Sandborn; G Y Melmed; D P B McGovern; E V Loftus; J M Choi; J H Cho; B Abraham; A Gutierrez; G Lichtenstein; S D Lee; C W Randall; D A Schwartz; M Regueiro; C A Siegel; M Spearman; G Kosutic; B Pierre-Louis; J Coarse; S Schreiber Journal: Aliment Pharmacol Ther Date: 2015-06-01 Impact factor: 8.171
Authors: William J Sandborn; Stefan Schreiber; Brian G Feagan; Paul Rutgeerts; Ziad H Younes; Ralph Bloomfield; Geoffroy Coteur; Juan Pablo Guzman; Geert R D'Haens Journal: Clin Gastroenterol Hepatol Date: 2011-05-13 Impact factor: 11.382
Authors: Filip Baert; Maja Noman; Severine Vermeire; Gert Van Assche; Geert D' Haens; An Carbonez; Paul Rutgeerts Journal: N Engl J Med Date: 2003-02-13 Impact factor: 91.245
Authors: G R Lichtenstein; R H Diamond; C L Wagner; A A Fasanmade; A D Olson; C W Marano; J Johanns; Y Lang; W J Sandborn Journal: Aliment Pharmacol Ther Date: 2009-04-21 Impact factor: 8.171
Authors: Johannan F Brandse; Ron A Mathôt; Desiree van der Kleij; Theo Rispens; Yaël Ashruf; Jeroen M Jansen; Svend Rietdijk; Mark Löwenberg; Cyriel Y Ponsioen; Sharat Singh; Gijs R van den Brink; Geert R D'Haens Journal: Clin Gastroenterol Hepatol Date: 2015-11-09 Impact factor: 11.382
Authors: Scott D Lee; David T Rubin; William J Sandborn; Charles Randall; Ziad Younes; Stefan Schreiber; David A Schwartz; Robert Burakoff; David Binion; Themos Dassopoulos; Razvan Arsenescu; Alexandra Gutierrez; Ellen Scherl; Cem Kayhan; Iram Hasan; Gordana Kosutic; Marshall Spearman; David Sen; Jason Coarse; Stephen Hanauer Journal: Inflamm Bowel Dis Date: 2016-08 Impact factor: 5.325
Authors: Diane R Mould; Richard N Upton; Jessica Wojciechowski; Becky L Phan; Stacy Tse; Marla C Dubinsky Journal: AAPS J Date: 2018-06-14 Impact factor: 4.009
Authors: Eugenia Shmidt; Gursimran Kochhar; Justin Hartke; Prianka Chilukuri; Joseph Meserve; Khadija Chaudrey; Jenna L Koliani-Pace; Robert Hirten; David Faleck; Morris Barocas; Michelle Luo; Karen Lasch; Brigid S Boland; Siddharth Singh; Niels Vande Casteele; Sashidhar Varma Sagi; Monika Fischer; Shannon Chang; Matthew Bohm; Dana Lukin; Keith Sultan; Arun Swaminath; David Hudesman; Nitin Gupta; Sunanda Kane; Edward V Loftus; William J Sandborn; Corey A Siegel; Bruce E Sands; Jean-Frederic Colombel; Bo Shen; Parambir S Dulai Journal: Inflamm Bowel Dis Date: 2018-10-12 Impact factor: 5.325
Authors: N Vande Casteele; B G Feagan; S Vermeire; M Yassine; J Coarse; G Kosutic; W J Sandborn Journal: Aliment Pharmacol Ther Date: 2017-11-21 Impact factor: 8.171
Authors: Niels Vande Casteele; Brian G Feagan; Douglas C Wolf; Anca Pop; Mohamed Yassine; Sara N Horst; Timothy E Ritter; William J Sandborn Journal: Inflamm Bowel Dis Date: 2021-07-27 Impact factor: 5.325